Clinical trials: Aripiprazole
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
HIV Infections
Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures…
- Trial name
- NCT00365339
- Testing
- Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Autism
Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism
The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.
- Trial name
- NCT03179787
- Testing
- Aripiprazole oral product
- Where
- Japan
- Volunteers
- 528 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
- Trial name
- NCT01646827
- Testing
- Aripiprazole IM Depot
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily…
- Trial name
- NCT03487783
- Testing
- Aripiprazole Oral Solution
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Otsuka Beijing Research Institute
Autistic Disorder
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).
- Trial name
- NCT01617460
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 86 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in…
- Trial name
- NCT02220712
- Testing
- OPC-14597 IMD
- Where
- 5 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).
This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00332241
- Testing
- Aripiprazole
- Where
- 9 sites in United States
- Volunteers
- 98 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major
Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)
To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.
- Trial name
- NCT01284218
- Volunteers
- 23,514 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia The trial is designed into…
- Trial name
- ASPIRE (NCT00706654)
- Testing
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg
- Where
- 98 sites in United States, Austria and 13 more
- Volunteers
- 937 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Dementia, Alzheimer Type
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
- Trial name
- NCT01438060
- Testing
- Aripiprazole (BMS-337039)
- Volunteers
- 232 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder Mania
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
- Trial name
- NCT00665366
- Testing
- Aripiprazole, Lithium, Valproate
- Where
- 73 sites in Austria, Czechia and 11 more
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.